Features of AKYNZEO® ready-to-use, single dose hanging vial1

  AKYNZEO Injection1 Cinvanti® injectable emulsion2 Fosaprepitant for injection3
Contains the following medication(s) fosnetupitant/palonosetron aprepitant fosaprepitant
How product is supplied ready-to-use solution in hanging vial injectable emulsion in vial lyophilized powder in vial
Clinical Pharmacology
Inhibits NK-1 pathway
Inhibits 5-HT3 pathway No No
NK-1 RA half-life 144 hours in cancer patients 9-13 hours in healthy subjects* 9-13 hours in healthy subjects*
5-HT3 RA half-life 58 hours in cancer patients N/A N/A
Administer 2 medications in a single product No No
Accessible via automated dispensing machine Orange Star Footnote Symbol No
Infused directly from the vial Orange Star Footnote Symbol No No
Does NOT require reconstitution or dilution Orange Star Footnote Symbol No No
Can administer simultaneously with IV dexamethasone No No
Contains NO polysorbate 80 No
Does NOT require refrigeration at any point during distribution, storage, or preparation No No

Orange Star Footnote Symbol=Specific to AKYNZEO injection (ready-to-use).

*Data not available in cancer patients.

Cinvanti IV infusion requires dilution.2

All trademarks are the property of their respective owners.

Pharmacological data cannot be used to make clinical comparisons of efficacy between treatments.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include netupitant/fosnetupitant and palonosetron fixed combination (AKYNZEO) as a NCCN Category 1 recommended option for parenteral MEC and HEC regimens4‡

  • When used in recommended antiemetic combination regimens on day 1.
  • 5-HT3=5-hydroxytryptamine; HEC=highly emetogenic chemotherapy; IV=intravenous; MEC=moderately emetogenic chemotherapy; NCCN=National Comprehensive Cancer Network; NK-1=neurokinin-1; RA=receptor antagonist.

AKYNZEO Limitations of Use
AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.